Retatrutide vs Semaglutide vs Tirzepatide: Comparing GLP-1 Research Peptides
Semaglutide, tirzepatide and retatrutide activate one, two and three metabolic receptors respectively. Here is how their receptor activity differs.
Semaglutide, tirzepatide and retatrutide are three incretin-pathway peptides studied extensively in metabolic research, and they form a clear receptor-level progression: semaglutide activates one receptor (GLP-1), tirzepatide activates two (GLP-1 and GIP), and retatrutide activates three (GLP-1, GIP and glucagon). Each additional receptor adds a distinct signalling pathway.
Semaglutide: Single-Receptor GLP-1 Agonist
Semaglutide is a modified GLP-1 analog carrying a C18 fatty-acid chain that binds reversibly to albumin, extending its half-life to roughly seven days. It binds GLP-1 receptors, which are expressed in pancreatic beta cells among other tissues, and activates cAMP signalling that stimulates glucose-dependent insulin secretion in islet models. Full detail on the semaglutide product page.
Tirzepatide: Dual GLP-1/GIP Agonist
Tirzepatide activates both the GLP-1 and GIP receptors from a single peptide. The GLP-1 component engages the same receptor as semaglutide, while the added GIP receptor activity is studied for its role in insulin secretion and adipocyte signalling in cell models.
Retatrutide: Triple GLP-1/GIP/Glucagon Agonist
Retatrutide (LY3437943) extends the mechanism one step further by adding glucagon receptor activation alongside GLP-1 and GIP. The GLP-1 and GIP components act on the same receptors as tirzepatide, while glucagon receptor activation adds a third signalling pathway in hepatocytes. Phase 2 reports were published in 2023.
Comparison Table
| Semaglutide | Tirzepatide | Retatrutide | |
|---|---|---|---|
| Receptors activated | GLP-1 | GLP-1 + GIP | GLP-1 + GIP + Glucagon |
| Half-life | ~7 days | ~5 days | ~6 days |
| Structural feature | C18 fatty-acid chain, albumin binding | Single peptide, dual receptor activity | Single peptide, triple receptor activity |
| Additional receptor-level pathway | None beyond GLP-1 | GIP receptor signalling | Hepatic glucagon receptor signalling |
Why the Receptor Count Matters Mechanistically
Each added receptor engages a separate signalling pathway, not a redundant one:
- GLP-1 receptor: a Gs-coupled receptor that raises intracellular cAMP; best characterised in pancreatic beta cells
- GIP receptor: also cAMP-coupled; expressed in pancreatic islets and adipocytes
- Glucagon receptor: expressed in hepatocytes, where it is studied for its role in hepatocyte signalling
This is why retatrutide is studied as a distinct mechanism rather than simply a “stronger” version of tirzepatide: it is the only one of the three that engages the glucagon receptor.
A Note on Head-to-Head Comparisons
No published study has directly compared all three compounds against each other. The table above is a receptor-level comparison, not a ranking.
For the full incretin-pathway lineup, see the related compounds in the catalogue.
Research Use Only
Semaglutide, tirzepatide and retatrutide as discussed here are supplied strictly for laboratory and research use. Milo-Lab gives no use or dosing advice, and nothing in this article constitutes medical advice. For research purposes only. Not for human consumption.
Interested in the peptides discussed in this article?
Browse our full catalog of research-grade peptides or contact us with questions about product specifications.